27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- AbbVie Inc (NYSE:ABBV) reports Q3 adjusted EPS of $3.33, higher than $2.83 reported a year ago and beating the consensus of $3.22.
- Overall sales increased 11.2% Y/Y to $14.34 billion, almost in line with the consensus of $14.32 billion.
- The immunology portfolio generated $6.67 billion in sales, +15.3% (14.9% on an operational basis).
- Hematologic oncology portfolio sales were $1.87 billion, +8.4% (+8.1%).
- Sales from the neuroscience portfolio reached $1.57 billion, +25.5% (+25%).
- Aesthetics portfolio sales increased 29.3% (+27.7%) to $1.25 billion.
- Adjusted gross margin expanded from 81.7% to 83.2%. The operating margin also improved from 48.8% to 51.1%.
- FY21 guidance: AbbVie raises FY21 adjusted EPS guidance from $12.52 - $12.62 to $12.63 - $12.67 (consensus of $12.59).
- The Company also increased the dividend by 8.5%, from $1.30 per share to $1.41, payable on February 15, 2022, to shareholders of record as of January 14, 2022.
- Price Action: ABBV shares are up 3.03% at $113.00 during the premarket session on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!